ob-002
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 5, 2019 (NCT04791007)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- C-C chemokine receptor type 5ANTAGONIST
CCR5 antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314995 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05940844 | Phase 1 | Jan 31, 2024 | ORION Sante |
| NCT04791007 | Early Phase 1 (Phase 1) | Oct 5, 2019 | ORION Sante, SCOPE International AG |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ORION Sante | Academic/Hospital | 2 | 2 | 1 | 2019 |
| SCOPE International AG | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1